C-Raf is associated with disease progression and cell proliferation in a subset of melanomas

Clinical Cancer Research

Volumn 15, Issue 18, 2009, Pages 5704-5713

  Jilaveanu, Lucia B ^a   Zito, Christopher R ^a   Aziz, Saadia A ^a   Conrad, Patricia J ^a   Schmitz, John C ^a,c   Sznol, Mario ^a   Camp, Robert L ^b   Rimm, David L ^b   Kluger, Harriet M ^a  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; C RAF PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAD; PROTEIN BCL 2; RAF PROTEIN; SMALL INTERFERING RNA; SORAFENIB; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IC 50; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZENESULFONATES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENE SILENCING; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; NEVUS; PHENOLS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RAF; PYRIDINES; RNA, SMALL INTERFERING; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; YOUNG ADULT;

EID: 70349445575     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0198     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Nashan D, Muller ML, Grab be S, Wustlich S, Enk A. Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine. J Eur Acad Dermatol Venereol 2007;21:1305-1318 (Pubitemid 350027157)
3. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003;104:527-532
4. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-κB and tumor progression. Cancer Res 2002;62:7335-7342 (Pubitemid 36025257)
5. Kolch W, Kotwaliwale A, Vass K, Janosch P. The role of Raf kinases in malignant transformation. Expert Rev Mol Med 2002;4:1-18.
6. Hagemann C, Rapp UR. Isotype-specific functions of Raf kinases. Exp Cell Res 1999;253:34-46.
7. Mikula M, Schreiber M, Husak Z, et al. Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J 2001;20:1952-1962 (Pubitemid 32397397)
8. Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ, Marais R. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 1999;18:2137-2148 (Pubitemid 29179171)
9. Diaz B, Barnard D, Filson A, MacDonald S, King A, Marshall M. Phosphorylation of Raf-1 serine 338-serine 339 is an essential regulatory event for Ras-dependent activation and biological signaling. Mol Cell Biol 1997;17:4509-4516 (Pubitemid 27318127)
10. Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 1997;272:4378-4383 (Pubitemid 27078513)
11. Emuss V, Garnett M, Mason C, Marais R. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res 2005;65:9719-9726 (Pubitemid 41541448)
12. Zebisch A, Staber PB, Delavar A, et al. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res 2006;66:3401-3408
13. Houben R, Becker JC, Kappel A, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 2004;3:6. (Pubitemid 38751386)
14. Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756-759 (Pubitemid 36231971)
15. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
16. Schmidt CA, Oettle H, Ludwig WD, et al. Overexpression of the Raf-1 proto-oncogene in human myeloid leukemia. Leuk Res 1994;18:409-413 (Pubitemid 24169822)
17. Riva C, Lavieille JP, Reyt E, Brambilla E, Lunardi J, Brambilla C. Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance. Eur J Cancer B Oral Oncol 1995;31B:384-391 (Pubitemid 26009168)
18. Mukherjee R, Bartlett JM, Krishna NS, Underwood MA, Edwards J. Raf-1 expression may influence progression to androgen insensitive prostate cancer. Prostate 2005;64:101-107 (Pubitemid 40734744)
19. McPhillips F, Mullen P, Monia BP, et al. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br J Cancer 2001;85:1753-1758 (Pubitemid 34081523)
20. Lau QC, Brusselbach S, Muller R. Abrogation of c-Raf expression induces apoptosis in tumor cells. Oncogene 1998;16:1899-1902 (Pubitemid 28197410)
21. Chen J, Fujii K, Zhang L, Roberts T, Fu H. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci U S A 2001;98:7783-7788 (Pubitemid 32642638)
22. Wang HG, Miyashita T, Takayama S, et al. Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene 1994;9:2751-2756 (Pubitemid 24254056)
23. Baumann B, Weber CK, Troppmair J, et al. Raf induces NF-κB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. Proc Natl Acad Sci U S A 2000;97:4615-4620 (Pubitemid 30238606)
24. Wang S, Ghosh RN, Chellappan SP. Raf-1 physically interacts with Rb and regulates its function: a link between mitogenic signaling and cell cycle regulation. Mol Cell Biol 1998;18:7487-7498 (Pubitemid 28533067)
25. Jamal S, Ziff EB. Raf phosphorylates p53 in vitro and potentiates p53-dependent transcriptional transactivation in vivo. Oncogene 1995;10:2095-2101
26. Lee M, Yoo HS. Human Raf-1 proteins associate with Rad24 and Cdc25 in cell-cycle checkpoint pathway of fission yeast, Schizosaccharomyces pombe. J Cell Biochem 2007;101:488-497 (Pubitemid 46698881)
27. Tian S, Mewani RR, Kumar D, et al. Interaction and stabilization of X-linked inhibitor of apoptosis by Raf-1 protein kinase. Int J Oncol 2006;29:861-867
28. Karasarides M, Chiloeches A, Hayward R, et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004;23:6292-6298
29. Dumaz N, Hayward R, Martin J, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006;66:9483-9491
30. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-1327 (Pubitemid 35373567)
31. Halaban R, Krauthammer M, Pelizzola M, et al. Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One 2009;4:e4563. Epub 2009 Feb 23.
32. McCarthy MM, Pick E, Kluger Y, et al. HSP90 as a marker of progression in melanoma. Ann Oncol 2008;19:590-594
33. McCarthy MM, DiVito KA, Sznol M, et al. Expression of tumor necrosis factor-related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res 2006;12:3856-3863 (Pubitemid 44000268)
34. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative in situ analysis of β-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 2006;66:5487-5494 (Pubitemid 43844977)
35. Smalley KS, Xiao M, Villanueva J, et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 2009;28:85-94.
36. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-867
37. Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008;68:4853-4861
38. Stevenson JP, Yao KS, Gallagher M, et al. Phase I clinical/ pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J Clin Oncol 1999;17:2227-2236 (Pubitemid 29318857)
39. Cunningham CC, Holmlund JT, Schiller JH, et al. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2000;6:1626-1631
40. Coudert B, Anthoney A, Fiedler W, et al. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. Eur J Cancer 2001;37:2194-2198 (Pubitemid 33001288)
41. Cripps MC, Figueredo AT, Oza AM, et al. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin Cancer Res 2002;8:2188-2192 (Pubitemid 34753589)
42. Dritschilo A, Huang CH, Rudin CM, et al. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res 2006;12:1251-1259 (Pubitemid 43342516)
43. Rudin CM, Marshall JL, Huang CH, et al. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res 2004;10:7244-7251
44. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109 (Pubitemid 39331023)
45. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenibin advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006;95:581-586 (Pubitemid 44325897)
46. Ahmad T, Marais R, Pyle L, et al. BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience. In: Proceedings of the American Society of Clinical Oncology New Orleans, LA; 2004.
47. Flaherty KT, Schiller J, Schuchter LM, et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008;14:4836-4842
48. Lackey K, Cory M, Davis R, et al. The discovery of potent cRaf1 kinase inhibitors. Bioorg Med Chem Lett 2000;10:223-226 (Pubitemid 30105376)
49. Chin PC, Liu L, Morrison BE, et al. The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism. J Neurochem 2004;90:595-608. (Pubitemid 38989390)
50. Bae D, Camilli TC, Ha NT, Ceryak S. Enhanced clonogenic survival induced by protein tyrosine phosphatase (PTP) inhibition after Cr(VI) exposure is mediated by c-Raf and Ras activity. Cell Signal 2009;21:727-736